Perceptive Advisors

Cerebral Therapeutics, Inc. is a pharmaceutical company that develops implanted drug-device combination therapies for the treatment of neurologic diseases. The company uses implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose for the formulation of anti-epileptic drug valproic acid, called CT-010, to treat refractory epilepsy. Cerebral Therapeutics, Inc. was formerly known as Cerebral Therapeutics LLC. The company was incorporated in 2010 and is based in Aurora, Colorado.

Surf Bio is a preclinical biopharmaceutical company focused on developing innovative therapeutic solutions using a novel biotechnology platform. This platform centers around a next-generation surfactant designed to enhance drug effectiveness for a variety of medical conditions, including diabetes, oncology, infectious diseases, and gene therapy. By improving therapeutic applications, Surf Bio aims to provide healthcare organizations worldwide with access to new and more effective treatments for patients facing critical health issues.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

Endeavor BioMedicines is a clinical-stage company focused on creating innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). The company is developing a small-molecule inhibitor aimed at addressing the underlying causes of this disease. This potential therapy not only seeks to halt the progression of IPF but may also reverse its effects, thereby providing healthcare professionals with precision treatment options for this terminal condition. By targeting the root causes of the disease, Endeavor BioMedicines aims to improve patient outcomes and enhance quality of life for those affected by pulmonary fibrosis.

Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. Mythic Therapeutics was founded in 2017 and is headquartered in Waltham, MA, USA.

Sermonix Pharmaceuticals, Inc. is a biotechnology company based in Columbus, Ohio, founded in 2014. The company specializes in the development and commercialization of female-specific oncology products, particularly focusing on late-stage women's health issues. Its primary product, lasofoxifene, is a selective estrogen receptor modulator designed for the treatment of vulvovaginal atrophy and for both the treatment and prevention of post-menopausal osteoporosis. Additionally, Sermonix is involved in developing pharmaceutical drugs aimed at treating ESR1-mutated metastatic breast and gynecological cancers, thereby enhancing the quality of care for women facing these health challenges.

Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology medicines tailored to individual patients. The company employs a proteomics-based platform to identify patients whose tumors are likely to respond to specific treatments, thereby enhancing the effectiveness of drug development. Acrivon's lead program is ACR-368, also known as prexasertib, which is currently in Phase 2 trials. Additionally, the pipeline includes preclinical programs that target critical components of the DNA Damage Response and cell cycle regulation pathways, specifically focusing on proteins such as WEE1 and PKMYT1. By leveraging these innovative approaches, Acrivon aims to improve therapeutic outcomes for cancer patients.

CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, founded in 2018. The company specializes in the development of treatments for cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, a novel aldosterone synthase inhibitor aimed at addressing resistant hypertension and primary aldosteronism. By advancing its promising clinical candidates, CinCor Pharma seeks to gain marketing approval for innovative therapies that can effectively address unmet medical needs in these critical areas of health.

A-Alpha Bio, Inc., founded in 2017 and based in Seattle, Washington, specializes in synthetic biology with a focus on drug development that targets multiple proteins. The company's flagship platform, AlphaSeq, offers innovative cell-based tools for quantitative and high-throughput measurement of protein interactions. This technology accelerates processes such as target discovery, library screening, and preclinical drug characterization, addressing significant bottlenecks in the industry. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in enhancing binding and specificity for various target proteins. The team comprises experts in synthetic biology, structural biology, and next-generation sequencing, all dedicated to advancing drug discovery methodologies.

Zentera Therapeutics is a biopharmaceutical company.

Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Pyxis Oncology, Inc. is a biotechnology company focused on developing antibody therapeutics that enhance the immune response against cancer. Founded in 2018 and based in Boston, Massachusetts, the company specializes in analyzing tumor antigen-specific tumor-infiltrating lymphocytes within hot tumors and tumor cell signaling pathways in cold tumors. This research informs the creation of novel antibody-based immunotherapies aimed at targeting difficult-to-treat cancers. Pyxis Oncology's goal is to develop next-generation therapeutics that not only kill tumor cells but also address the underlying issues that facilitate cancer's proliferation and immune evasion, ultimately improving the quality of life for patients.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Pipeline Therapeutics Inc. is a biotechnology company focused on developing and commercializing small molecules aimed at neuroregeneration, which includes promoting synaptogenesis, remyelination, and axonal repair. Based in San Diego, California, the company’s lead product candidate, PIPE-505, is a gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics is advancing earlier-stage programs, such as PIPE-307, which target remyelination and axonal repair to address various neurological disorders, including multiple sclerosis. Founded in 2017, the company aims to harness the body's natural repair mechanisms to facilitate recovery from neurological damage.

Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers in patients of all ages, with an initial emphasis on pediatric patients. Founded in 2018 and headquartered in South San Francisco, California, the company aims to address the critical needs of children and adults diagnosed with cancer by creating innovative treatments derived from the biology of childhood cancer. Day One Biopharmaceuticals prioritizes programs that can be swiftly brought to market, thereby providing timely options for families facing cancer diagnoses. Its lead product candidate, DAY101, is an oral, brain-penetrant pan-RAF kinase inhibitor designed to target specific cancer types. The company seeks to license and acquire promising therapeutic products from research institutions and other biotechnology and pharmaceutical companies, striving to enhance the treatment landscape for underserved populations.

DarioHealth Corp. is a digital health company that specializes in developing and commercializing proprietary technology for laboratory testing via smartphones and mobile devices. Its flagship product, the Dario Smart Diabetes Management Solution, integrates a cloud-based software application with a compact blood glucose monitoring device. This solution enables users to manage their diabetes through real-time data tracking, coaching, and support, while also providing alerts and analysis of health trends. DarioHealth markets its products directly to consumers and through retail pharmacies, hospitals, and online channels. The company also offers a digital platform, DarioEngage, to enhance user engagement and support in managing chronic illnesses. Founded in 2011 and headquartered in Caesarea, Israel, DarioHealth emphasizes personalized, evidence-based interventions driven by data analytics and individual coaching, addressing various health concerns such as diabetes, hypertension, and weight management.

Prometheus Biosciences, formerly known as Prometheus Laboratories, is a biotechnology company focused on developing and commercializing innovative pharmaceutical and diagnostic products, primarily for gastrointestinal diseases such as inflammatory bowel disease (IBD). Based in San Diego, California, the company offers a range of diagnostic tests, including Anser IFX, Anser ADA, and IBD sgi Diagnostic, which enable healthcare providers to monitor treatment and optimize patient care. Prometheus also markets therapeutic agents, such as Entocort EC and Imuran, for managing conditions like Crohn's disease and rheumatoid arthritis. Additionally, it provides genetic and serologic testing for celiac disease and lactose intolerance, among other disorders. With a commitment to precision medicine, Prometheus aims to enhance individualized patient care through its advanced diagnostic capabilities and therapeutic solutions. The company was founded in 1995 and operates as a subsidiary of Precision IBD, Inc.

LianBio is a biopharmaceutical company based in Shanghai, China, with an additional office in Princeton, New Jersey. Founded in 2019, the company focuses on the discovery and development of therapeutic drugs aimed at treating oncology and cardiorenal diseases, as well as other medical conditions. LianBio's mission is to enhance access to innovative medicines by partnering with leading organizations in the field to leverage advanced scientific discoveries. The company is dedicated to addressing unmet medical needs in Greater China and other Asian markets by in-licensing assets and building a diverse pipeline of clinically validated product candidates. Its portfolio aims to establish new standards of care across various therapeutic areas, including cardiovascular, oncology, ophthalmology, inflammatory diseases, and respiratory conditions.

Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.

Escient Pharmaceuticals, Inc., a biotechnology company, develops and manufactures G protein-coupled receptor (GPCR)-targeted drugs for treating neuro-immuno-inflammatory and autoreactive diseases. The company focuses on unleashing the therapeutic potential of specific orphan GPCRs, including the novel family of Mas-Related G-Protein Receptors (Mrgprs) for neuro-immuno-inflammatory and autoreactive diseases. Escient Pharmaceuticals, Inc. was formerly known as Mas Therapeutics, Inc. The company was founded in 2017 and is based in San Diego, California.

I-Mab HK is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the areas of cancer and autoimmune disorders. The company is engaged in developing a diverse pipeline of product candidates, including Felzartamab, a CD38 antibody in Phase III trials for multiple myeloma, and Eftansomatropin, a long-acting human growth hormone for pediatric growth hormone deficiency. Other notable candidates include Olamkicept, an IL-6 blocker for ulcerative colitis, and Enoblituzumab, a B7-H3 antibody for head and neck cancer. I-Mab HK also has preclinical compounds targeting various conditions, including cancers and autoimmune diseases. The company has established strategic collaborations, such as with AbbVie, to enhance its development efforts. Founded in 2014 and headquartered in Shanghai, I-Mab HK is dedicated to advancing therapies that improve patient outcomes across various therapeutic areas.

Rain Therapeutics Inc. is a biotechnology company focused on developing targeted therapies for cancer patients, particularly those with unmet medical needs. Established in 2017 and based in Newark, California, the company specializes in small molecule therapeutics. Its lead product, RAIN-32, is a small molecule MDM2 inhibitor aimed at treating well-differentiated and de-differentiated liposarcoma. Additionally, Rain Therapeutics is developing tarloxotinib, a hypoxia-activated pan-HER inhibitor currently undergoing clinical trials for non-small cell lung cancer. The company emphasizes identifying cancers driven by specific oncogenic mutations and evaluates sub-populations where existing treatment options are inadequate. Through collaboration with a global network of scientific and thought leaders, Rain Therapeutics seeks to align its therapeutic innovations with the needs of these cancer populations.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

AsclepiX Therapeutics, Inc. is a biopharmaceutical company focused on the design and development of innovative treatments for diseases related to abnormal blood vessel growth, specifically through the use of short biomimetic anti-angiogenic and anti-lymphangiogenic peptides. The company's lead candidates, including AXT107, AXT201, AXT301, and AXT501, target conditions such as diabetic macular edema, wet age-related macular degeneration, and macular edema following retinal vein occlusion, which are among the leading causes of blindness. Additionally, AXT201, AXT301, and AXT501 are being explored for their potential in treating various solid tumors. AsclepiX leverages advanced computational biology, bioinformatics, and the latest developments in biomaterials to enhance drug delivery systems, aiming to create long-lasting biodegradable nanoparticles that can effectively deliver its therapeutic peptides. Incorporated in 2011 and based in Baltimore, Maryland, AsclepiX Therapeutics is committed to addressing unmet medical needs in ophthalmology, oncology, and other diseases driven by angiogenesis and lymphangiogenesis.

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

Athira Pharma is a clinical-stage drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is derived from the word Athir, the energy that reaches everyone. It captures its mission to develop therapies that can reach and positively impact everyone.

Atea Pharmaceuticals is a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe human viral infections. It caters to the healthcare industry and engages in the discovery and development of antiviral therapeutics that enable patients to have treatment for infections caused by RNA and DNA viruses. Atea Pharmaceuticals was established in 2014 and is headquartered in Boston, Massachusetts.

COMPASS Pathways is a mental health care company focused on developing innovative treatments for mental health conditions. It specializes in the formulation of COMP360, a psilocybin-based therapy currently undergoing Phase IIb clinical trials aimed at treating patients with treatment-resistant depression. The company operates across multiple sites in Europe and North America, conducting large-scale clinical trials to evaluate the efficacy and safety of its psilocybin therapy. Founded in 2016 and incorporated in 2020, COMPASS Pathways is headquartered in Altrincham, Cheshire, United Kingdom. The company's mission is to enhance patient access to evidence-based mental health solutions.

Agile Therapeutics, Inc. is a women's healthcare company dedicated to developing and commercializing prescription contraceptive products. The company’s lead product, Twirla, is a once-weekly transdermal contraceptive patch that delivers a low dose of levonorgestrel and ethinyl estradiol. Agile Therapeutics is also advancing a pipeline of related products, including various line extensions of Twirla and additional transdermal contraceptive options. These include regimens designed to extend menstrual cycles or provide shorter and lighter periods, as well as a progestin-only patch intended for women who cannot or prefer not to use estrogen. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics aims to address the unmet healthcare needs of women through innovative contraceptive solutions.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

Cerebral Therapeutics, Inc. is a pharmaceutical company that develops implanted drug-device combination therapies for the treatment of neurologic diseases. The company uses implanted, refillable catheter and pump system to deliver a continuous intracerebroventricular (ICV) dose for the formulation of anti-epileptic drug valproic acid, called CT-010, to treat refractory epilepsy. Cerebral Therapeutics, Inc. was formerly known as Cerebral Therapeutics LLC. The company was incorporated in 2010 and is based in Aurora, Colorado.

Quellis Biosciences, Inc. is a biopharmaceutical company based in Waltham, Massachusetts, dedicated to developing innovative monoclonal antibody therapies for patients with rare diseases. Founded in 2017, the company aims to create next-generation treatments that enhance patient outcomes, particularly for conditions that are underserved by existing therapies. Quellis is supported by a team with extensive expertise in monoclonal antibody discovery and development, as well as experience in biotech investment and company formation. Collaborating with partners from the biotech incubator Viridian LLC and the accelerator Xontogeny LLC, Quellis is focused on optimizing multiple antibody leads to ensure effective therapeutic performance. Their mission is to deliver meaningful medicines that significantly improve the lives of patients facing serious health challenges.

Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company based in New York, focused on developing innovative small molecule therapeutics for cancer treatment. Established in 2014, the company aims to target fundamental biological pathways associated with various cancers. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader currently undergoing Phase I/II clinical trials for advanced or metastatic breast cancer. Additionally, Zentalis is advancing several other candidates: ZN-c3, a WEE1 inhibitor in trials for advanced solid tumors; ZN-d5, a selective B-cell lymphoma 2 inhibitor for hematological cancers; and ZN-e4, an irreversible inhibitor of the mutant epidermal growth factor receptor, also in Phase I/II trials for advanced non-small cell lung cancer. Through its Integrated Discovery Engine, Zentalis seeks to discover and develop novel compounds with potentially differentiated therapeutic profiles.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, specializing in the development of oral therapeutics for autoimmune diseases. Founded in 2017, the company focuses on innovative treatments for conditions such as inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Its lead product candidate, NX-13, is a novel, gut-selective agonist targeting the NLRX1 pathway. The company also has a diverse pipeline that includes other internally discovered compounds aimed at novel immunometabolic pathways. By developing first-in-class therapeutics, Landos Biopharma seeks to provide effective treatment options for patients suffering from autoimmune conditions.

Foamix Pharmaceuticals Inc. a pharmaceutical company, engages in development and commercialization of proprietary, innovative, and differentiated topical drugs for dermatological conditions. It offers Molecule Stabilizing Technology (MST) platform. The company was incorporated in 2014 and is based in Bridgewater, New Jersey. Foamix Pharmaceuticals Inc. operates as a subsidiary of Menlo Therapeutics Inc.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, dedicated to leveraging the body's natural biology to repair or reverse damage from various degenerative diseases. The company employs a unique Progenitor Cell Activation approach, utilizing combinations of small molecules to stimulate progenitor cells to regenerate functional tissue. Its lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at addressing the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is developing therapies for a variety of degenerative conditions, including multiple sclerosis and ailments affecting muscle, skin, gastrointestinal tract, and bone health. The company has also established a collaboration agreement with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics is focused on disease modification through innovative therapeutic strategies.

Neptune Wellness Solutions Inc. is an integrated health and wellness company based in Laval, Canada, focusing on lifestyle brands and consumer packaged goods. The company develops products under the Forest Remedies and Ocean Remedies brands and offers comprehensive solutions in various health and wellness sectors, including legal cannabis, nutraceuticals, and white label consumer goods. Neptune specializes in extraction and purification services from cannabis and hemp biomass, alongside providing raw material sourcing, formulation, and quality control for omega-3 and hemp-derived ingredients. Its manufacturing capabilities extend to a range of product forms, including tinctures, sprays, topicals, and edibles. Additionally, Neptune has engaged in a collaboration with International Flavors & Fragrances to co-develop hemp-derived products for the mass retail and health markets. With over 50 years of combined experience, the company emphasizes social responsibility, sustainability, and innovation in redefining health and wellness.

PanTheryx is a U.S. medical nutrition company focused on the research, development, and commercialization of products that promote intestinal health. The company is engaged in the discovery and development of its proprietary technology platform, advancing clinical testing, and the commercialization of its products that both address the specific dietary needs of children with infectious diarrhea, and support overall intestinal health. The company’s medical nutrition products are regulated in three FDA categories: medical foods, food for special dietary use, and dietary supplements. PanTheryx was founded in 2007 by Mark A. Braman and is based in Boulder, Colorado.

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company specializes in developing internal drug discovery programs focused on G-protein coupled receptors (GPCRs) to address unmet medical needs. Utilizing its proprietary CONFO® technology, Confo Therapeutics stabilizes inherently unstable functional conformations of GPCRs, providing a robust starting point for drug discovery. This approach reveals previously inaccessible structural features of these receptors, facilitating the identification of novel agonists that enhance therapeutic interventions.

Athenex, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and related conditions. Founded in 2003 and headquartered in Buffalo, New York, Athenex operates across North America and Asia, aiming to become a global leader in cancer treatment. The company has three primary segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Its clinical pipeline includes notable Orascovery product candidates, such as Oral Paclitaxel for metastatic breast cancer and various other oral formulations targeting different cancer types. Additionally, Athenex is developing Src Kinase inhibitors for skin cancers and immunomodulatory therapies, including T Cell Receptor Engineered T Cells and arginine deprivation therapy. Through collaborations and strategic partnerships, Athenex is engaged in extensive research and development activities to advance its therapeutic offerings and improve patient outcomes.

Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for underserved patient populations affected by rare diseases and cancer. Founded in 2017 and headquartered in Stamford, Connecticut, the company’s lead product candidate, nirogacestat, is an oral small molecule gamma secretase inhibitor currently in Phase III trials for treating desmoid tumors. Other significant candidates include mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for relapsed or refractory multiple myeloma. The company is also exploring additional therapies, such as BGB-3245, an investigational oral inhibitor targeting BRAF mutations, currently in Phase I trials. SpringWorks has established collaborations with several biotechnology and pharmaceutical firms to enhance its research and development efforts.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.

BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.

Vyome Therapeutics focuses on developing innovative treatments for antibiotic-resistant acne and other pathogens through a unique pipeline of antibiotics designed to slow the development of resistance. The company's product portfolio includes VB 1953, its lead molecule targeting the significant unmet needs in the resistant acne market, along with various anti-dandruff products such as VB 001 (a leave-on scalp care treatment), VB 2421 (a hair gel), VB 3222 (a wash-off shampoo), and VB 7731 (a Ketoconazole emulsion gel). Established in 2010 and based in Princeton, New Jersey, the company incorporates advanced research and development capabilities, including formulation, analytical, and clinical divisions. Vyome's management team boasts extensive expertise in dermatology and has a proven track record of successfully launching numerous products. The firm is committed to addressing refractory skin conditions and aims to bring its innovative therapies to market effectively.

Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.

Medicrea International SA specializes in the design, manufacture, and distribution of spinal implants, operating both in France and internationally. Established in 1990 and headquartered in Rillieux-la-Pape, France, the company offers a comprehensive range of products, including various systems for thoraco-lumbar fixation, cervical interbody devices, and specialized implants for treating conditions such as scoliosis, degenerative diseases, and trauma. Notable product lines include the PASS series, which encompasses polyaxial and posterior fixation systems, as well as the IMPIX series, featuring sterile PEEK Optima cervical and lumbar interbody devices. Medicrea focuses on delivering innovative technologies aimed at improving patient outcomes and supporting healthcare professionals in surgical procedures. The company has been dedicated to advancing spinal care, leveraging over 18 years of experience in the field. As of late 2020, Medicrea operates as a subsidiary of Covidien Group S.a.r.l.

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing targeted gene therapy products using evolved adeno-associated virus vectors. The company has a diverse portfolio focusing on three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Key product candidates include 4D-125, currently in a Phase I/II clinical trial for treating X-linked retinitis pigmentosa; 4D-110, in a Phase I trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is developing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. The company aims to address unmet medical needs through its innovative gene therapies.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

Athenex, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and related conditions. Founded in 2003 and headquartered in Buffalo, New York, Athenex operates across North America and Asia, aiming to become a global leader in cancer treatment. The company has three primary segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Its clinical pipeline includes notable Orascovery product candidates, such as Oral Paclitaxel for metastatic breast cancer and various other oral formulations targeting different cancer types. Additionally, Athenex is developing Src Kinase inhibitors for skin cancers and immunomodulatory therapies, including T Cell Receptor Engineered T Cells and arginine deprivation therapy. Through collaborations and strategic partnerships, Athenex is engaged in extensive research and development activities to advance its therapeutic offerings and improve patient outcomes.

Rain Therapeutics Inc. is a biotechnology company focused on developing targeted therapies for cancer patients, particularly those with unmet medical needs. Established in 2017 and based in Newark, California, the company specializes in small molecule therapeutics. Its lead product, RAIN-32, is a small molecule MDM2 inhibitor aimed at treating well-differentiated and de-differentiated liposarcoma. Additionally, Rain Therapeutics is developing tarloxotinib, a hypoxia-activated pan-HER inhibitor currently undergoing clinical trials for non-small cell lung cancer. The company emphasizes identifying cancers driven by specific oncogenic mutations and evaluates sub-populations where existing treatment options are inadequate. Through collaboration with a global network of scientific and thought leaders, Rain Therapeutics seeks to align its therapeutic innovations with the needs of these cancer populations.

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing innovative treatments for transthyretin amyloidosis (ATTR), a disease caused by the misfolding of the transthyretin protein. The company is advancing its lead drug candidate, AG10, which is currently in phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize the tetrameric form of transthyretin, effectively preventing the molecular processes that lead to the development of ATTR. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, Inc., which is dedicated to creating genetically targeted therapies to enhance patient outcomes.

Crinetics Pharmaceuticals discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers. Their programs are derived from internal discovery efforts and use objective hormonal biomarker endpoints for preclinical and clinical studies to reduce both the risk and cost to achieve meaningful clinical data. Crinetics is seeking motivated partners to help advance Their programs to become commercially successful products.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

Partner Therapeutics, Inc. is an oncology company based in Lexington, Massachusetts, focused on developing and commercializing approved and late-stage cancer therapies. The company aims to improve treatment outcomes and reduce healthcare costs by providing a range of cancer treatments, from primary therapies to supportive care. One of its key products is Leukine, which promotes the growth of white blood cells, enhancing patients' immune responses during cancer treatment. Formerly known as Partners Oncology, Inc., the company rebranded in November 2017. Partner Therapeutics serves as a vital link between researchers and healthcare professionals, facilitating the advancement of cancer therapies.

Vitruvias Therapeutics is a start-up generic pharmaceutical company based in Montgomery, Alabama, founded in 2013. The company specializes in developing niche topical generic products that are available only by prescription. Focusing on complex active pharmaceutical ingredients (APIs) and challenging finished dosage forms, Vitruvias Therapeutics aims to address the difficulties associated with manufacturing these products. By leveraging strategic partnerships, the company seeks to overcome manufacturing complexities and raw material sourcing challenges, thereby enhancing the availability of essential generic medications. The name Vitruvias is inspired by Leonardo da Vinci’s "Vitruvian Man," symbolizing the ideal proportions of the human figure, reflecting the company's commitment to precision in pharmaceutical development.

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company based in Blacksburg, Virginia, specializing in the development of oral therapeutics for autoimmune diseases. Founded in 2017, the company focuses on innovative treatments for conditions such as inflammatory bowel disease (IBD), Crohn's disease, and ulcerative colitis. Its lead product candidate, NX-13, is a novel, gut-selective agonist targeting the NLRX1 pathway. The company also has a diverse pipeline that includes other internally discovered compounds aimed at novel immunometabolic pathways. By developing first-in-class therapeutics, Landos Biopharma seeks to provide effective treatment options for patients suffering from autoimmune conditions.

BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to discovering and developing biologic therapeutics for cancer treatment. The company utilizes a proprietary platform known as engineered toxin bodies to create targeted therapies. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. In addition, the company is developing other candidates, including MT-4019, which targets CD38, and has collaborations with Takeda Pharmaceutical Company and Vertex Pharmaceuticals. These partnerships aim to enhance treatment options for conditions like multiple myeloma and improve outcomes in hematopoietic stem cell transplants. Molecular Templates continues to expand its pipeline with additional compounds targeting various cancers.

Dova Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company based in Durham, North Carolina, that specializes in acquiring, developing, and commercializing drug candidates for thrombocytopenia, a condition characterized by low platelet counts. The company's primary product candidate, DOPTELET, is approved for treating thrombocytopenia in adult patients with chronic liver disease who are preparing for a medical procedure. Additionally, Dova is developing DOPTELET for other indications, including chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Founded in 2016, Dova Pharmaceuticals operates as a subsidiary of Swedish Orphan Biovitrum AB, focusing on addressing rare diseases with significant unmet medical needs.

Xontogeny LLC, founded in 2016 and based in Boston, Massachusetts, is a life sciences accelerator that focuses on the development of pharmaceuticals and related technologies. The company aims to enhance the success rates of early-stage drug and technology ventures by providing strategic guidance, operational support, and leadership to entrepreneurs. By partnering closely with founding scientists and innovators, Xontogeny promotes a more efficient development model that aligns with the vision of its partners while benefiting company founders and early equity holders. The firm primarily invests in the healthcare and life science sectors, striving to accelerate the advancement of life science technologies.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is an oral therapy currently in Phase I/IIa clinical trials for the treatment of phenylketonuria. Additionally, Synlogic is developing SYNB1891, an intratumoral synthetic biotic medicine that is undergoing Phase I clinical trials for the treatment of solid tumors and lymphoma. The company is also exploring synthetic biotics for more common conditions, including inflammatory bowel disease and secondary hyperoxaluria. Synlogic has established a collaboration with Ginkgo Bioworks to advance its development of these innovative therapies.

Vensun Pharmaceuticals, Inc. is a pharmaceutical company based in Yardley, Pennsylvania, focused on developing a diverse portfolio of generic prescription products across various therapeutic categories and dosage forms. Established in 2011, Vensun actively collaborates with strategic partners both domestically and internationally to co-develop its products. The company has filed multiple Abbreviated New Drug Applications (ANDAs) with the FDA and currently has over 30 products in active development. Vensun is also seeking further partnerships, strategic alliances, and product acquisitions to expand its development portfolio, aiming to provide enhanced pharmaceutical options for clinicians and healthcare professionals in the U.S. generic market.

Vyome Therapeutics focuses on developing innovative treatments for antibiotic-resistant acne and other pathogens through a unique pipeline of antibiotics designed to slow the development of resistance. The company's product portfolio includes VB 1953, its lead molecule targeting the significant unmet needs in the resistant acne market, along with various anti-dandruff products such as VB 001 (a leave-on scalp care treatment), VB 2421 (a hair gel), VB 3222 (a wash-off shampoo), and VB 7731 (a Ketoconazole emulsion gel). Established in 2010 and based in Princeton, New Jersey, the company incorporates advanced research and development capabilities, including formulation, analytical, and clinical divisions. Vyome's management team boasts extensive expertise in dermatology and has a proven track record of successfully launching numerous products. The firm is committed to addressing refractory skin conditions and aims to bring its innovative therapies to market effectively.

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative medicines to meet unmet medical needs both in the United States and internationally. The company offers several marketed products, including Sympazan, an oral soluble film for treating Lennox-Gastaut syndrome; Suboxone, a sublingual film for opioid dependence; and Zuplenz, an oral soluble film for nausea and vomiting related to chemotherapy and post-operative recovery. Additionally, Aquestive's proprietary product candidates include Libervant, a buccal film for epileptic seizures, and Exservan, an oral film for Amyotrophic Lateral Sclerosis. The company's pipeline also features AQST-108, a sublingual film for anaphylaxis, AQST-305 for acromegaly, and APL-130277 for Parkinson's disease. Established in 2004 and headquartered in Warren, New Jersey, Aquestive Therapeutics leverages its proprietary technologies to address complex healthcare challenges and partners with other pharmaceutical companies to enhance drug delivery methods.

Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's pipeline features several drug candidates, including Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies aimed at treating various solid tumors, including breast and endometrial cancers in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Another candidate, AR-12, has completed Phase I clinical studies for the treatment of solid tumors and hematological malignancies, and is also undergoing pre-clinical studies for various anti-microbial targets. Additionally, AR-42, an orally available therapy, is in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. Arno Therapeutics has established license agreements with multiple institutions and a co-development agreement with Leica Biosystems Newcastle Ltd., and is headquartered in Flemington, New Jersey.

Ardelyx, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for cardiorenal diseases. Headquartered in Fremont, California, Ardelyx's lead product candidate, tenapanor, has successfully completed Phase 3 clinical trials for treating irritable bowel syndrome with constipation and is also in Phase 3 trials for managing hyperphosphatemia in end-stage renal disease patients undergoing dialysis. The company is advancing RDX013, a small molecule potassium secretagogue, aimed at treating hyperkalemia. Ardelyx is also developing RDX5791, an oral NHE3 sodium transport inhibitor targeting constipation-predominant irritable bowel syndrome and excess dietary sodium absorption, currently in Phase 2 trials. Additionally, RDX002 and RDX009, which inhibit phosphate absorption and target type 2 diabetes, respectively, are in preclinical development. Ardelyx emphasizes non-systemic oral therapeutics that minimize side effects while effectively addressing metabolic disorders. Since its founding in 2007, the company has secured significant funding to support its research and development efforts.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, specializing in the development and commercialization of therapeutics for rare and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a synthetic oral cannabinoid receptor type 2 (CB2) agonist currently in Phase III trials for systemic sclerosis and dermatomyositis, as well as Phase IIb trials for systemic lupus erythematosus and cystic fibrosis. In addition, Corbus is advancing CRB-4001, a peripherally-restricted cannabinoid receptor type 1 (CB1) inverse agonist, targeting conditions such as nonalcoholic steatohepatitis (NASH). Corbus has established a licensing agreement with Jenrin Discovery, LLC, to develop a library of over 600 compounds, and maintains a strategic collaboration with Kaken Pharmaceutical Co., Ltd. for lenabasum's development in Japan. The company was founded in 2009 and demonstrates a commitment to addressing unmet medical needs in its focused therapeutic areas.

AVEO Oncology is a biopharmaceutical company engaged in the development and commercialization of targeted therapies for oncology and other unmet medical needs. The company's lead product, tivozanib, is an oral, once-daily inhibitor of vascular endothelial growth factor receptors, primarily indicated for renal cell carcinoma (RCC). AVEO has completed a Phase III trial (TIVO-3) for tivozanib and is conducting a Phase Ib/II trial combining it with Opdivo, an immune checkpoint inhibitor. Additionally, AVEO is developing Ficlatuzumab, an antibody currently in Phase II trials targeting various cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company's preclinical pipeline includes AV-380, aimed at cachexia, and AV-353, for pulmonary arterial hypertension. AVEO has established multiple collaboration agreements with various pharmaceutical companies and is involved in clinical trials assessing IMFINZI, an antibody targeting PD-L1. Headquartered in Boston, Massachusetts, AVEO was incorporated in 2001 and has a focus on advancing cancer therapeutics through its proprietary cancer biology platform.

Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's pipeline features several drug candidates, including Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies aimed at treating various solid tumors, including breast and endometrial cancers in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Another candidate, AR-12, has completed Phase I clinical studies for the treatment of solid tumors and hematological malignancies, and is also undergoing pre-clinical studies for various anti-microbial targets. Additionally, AR-42, an orally available therapy, is in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. Arno Therapeutics has established license agreements with multiple institutions and a co-development agreement with Leica Biosystems Newcastle Ltd., and is headquartered in Flemington, New Jersey.

Zymeworks Inc. is a clinical-stage biopharmaceutical company based in Vancouver, Canada, that specializes in the discovery, development, and commercialization of biotherapeutics, primarily for cancer treatment. The company’s leading candidates include ZW25, a bispecific antibody currently undergoing Phase I and II clinical trials targeting various cancers, and ZW49, a bispecific antibody-drug conjugate in Phase I trials for advanced HER2-expressing cancers. Zymeworks employs advanced computational biotechnology techniques, utilizing proprietary molecular modeling and high-performance computing to optimize therapeutic antibodies and other protein-based therapeutics. The company has established strategic partnerships and collaborations with several major pharmaceutical firms, including Merck, Eli Lilly, and Bristol-Myers Squibb, among others, to enhance its research and development efforts. Founded in 2003, Zymeworks continues to focus on developing innovative solutions for cancer and other serious diseases.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing innovative treatments for serious eye diseases. Founded in 2011 and based in Alpharetta, Georgia, the company utilizes a proprietary ocular microinjection platform to deliver therapies directly to specific compartments of the eye, including the retina and choroid. Its lead product, XIPERE, is a suprachoroidal injectable suspension of triamcinolone acetonide, targeting macular edema associated with conditions such as uveitis and diabetic macular edema. Additionally, Clearside is advancing CLS-AX, an axitinib formulation for suprachoroidal injection. The company's novel SCS Microinjector allows for a non-surgical, repeatable procedure aimed at preserving and restoring vision in patients with sight-threatening eye diseases.

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 biosimilar products, two of which are currently in clinical development. The company employs its BioSymphony biosimilars business model to achieve accelerated development and technical excellence in order to create affordable medicines for patients around the world.

CytomX Therapeutics is an early stage, privately-funded biotechnology company developing Probodiesâ„¢, proteolytically-activated antibodies. Probodies, by their ability to site-direct the activity of antibodies, will result in an improved therapeutic index for validated targets as well enable the drugging of targets with broad tissue expression. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

Alliqua BioMedical, a regenerative technologies company based in Yardley, Pennsylvania, specializes in the development, manufacturing, and marketing of innovative medical products for soft tissue repair and replacement. The company offers a range of proprietary products, including MIST Ultrasound Healing Therapy, a noncontact low-frequency ultrasound treatment that promotes healing, and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, both of which are human biologic regenerative technologies. Additionally, Alliqua markets wound dressings such as SilverSeal Hydrogel, an antimicrobial option, and Hydress, a moist wound dressing. The company also provides contract manufacturing services for high water content hydrogels used in various applications, including wound care, medical diagnostics, and transdermal drug delivery. Alliqua aims to advance its projects in active ingredients and transdermal drug delivery systems as well as enhance its presence in advanced wound care solutions.

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options and a patient-centric focus. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with innovative mechanisms of action.

Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating cancers and rare diseases driven by genomic abnormalities. The company’s pipeline includes avapritinib, which targets systemic mastocytosis and gastrointestinal stromal tumors, and BLU-263, an oral KIT inhibitor for indolent systemic mastocytosis and other mast cell disorders. Additionally, fisogatinib is in Phase I trials for advanced hepatocellular carcinoma, while pralsetinib targets RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Other investigational compounds include BLU-782, aimed at treating fibrodysplasia ossificans progressive. Established in 2008 and based in Cambridge, Massachusetts, Blueprint Medicines utilizes its proprietary chemical library and Insights-to-Validation Platform to develop personalized therapies that address specific molecular drivers of cancer and the challenges posed by resistance mechanisms. The company has formed collaboration agreements with several pharmaceutical entities to enhance its research and development efforts.

Zynerba Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company's lead product, Zygel, is a patent-protected cannabidiol gel currently undergoing Phase II clinical trials for various conditions, including developmental and epileptic encephalopathies, autism spectrum disorder, pediatric behavioral symptoms associated with 22q11.2 deletion syndrome, and fragile X syndrome. Zynerba aims to utilize modern drug delivery technology to provide sustained and controlled cannabinoid delivery while minimizing adverse effects commonly associated with oral dosing. Founded in 2007 and headquartered in Devon, Pennsylvania, Zynerba was formerly known as AllTranz, Inc. and rebranded in August 2014.

Bellicum Pharmaceuticals is a clinical-stage biopharmaceutical company based in Houston, Texas, focused on developing innovative cellular immunotherapies for the treatment of hematological cancers and solid tumors. The company is advancing its product candidates, including BPX-601, an autologous GoCAR-T therapy aimed at solid tumors expressing prostate stem cell antigen, and BPX-603, a dual-switch GoCAR-T therapy targeting solid tumors that express human epidermal growth factor receptor 2. Bellicum utilizes its proprietary Chemical Induction of Dimerization technology platform, which allows for real-time control of immune system components to enhance therapeutic efficacy. The company collaborates with various institutions, including Adaptimmune Therapeutics and Baylor College of Medicine, to further its research and development efforts. Founded in 2004, Bellicum Pharmaceuticals continues to make strides in cancer treatment through its novel immunotherapeutic approaches.

Virobay, Inc. operates as an anti-viral drug discovery and development company. It engages in developing, investigating, and creating treatments for hepatitis C, such as protease and polymerase inhibitors. The company was founded in 2006 and is headquartered in Menlo Park, California.

Otonomy, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for ear-related diseases and disorders. The company offers OTIPRIO, a ciprofloxacin otic suspension used during tympanostomy tube placement surgery in pediatric patients. Otonomy is advancing several product candidates, including OTIVIDEX, a sustained-release formulation of dexamethasone currently in Phase III trials for Ménière's disease, and OTO-313, which targets tinnitus and is in Phase I/II trials. Additionally, OTO-413 aims to treat cochlear synaptopathy and related hearing difficulties, while OTO-510 seeks to prevent hearing loss from cisplatin treatment. Another candidate, OTO-6XX, focuses on hair cell regeneration for severe hearing loss. Founded in 2008, Otonomy collaborates with various institutions and companies to enhance its research and development efforts in localized drug delivery for otologic disorders.

Arno Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cancer and other life-threatening diseases. The company's pipeline features several drug candidates, including Onapristone, a type 1 anti-progestin hormone blocker currently in Phase I/II clinical studies aimed at treating various solid tumors, including breast and endometrial cancers in post-menopausal women, as well as advanced castration-resistant prostate cancer in men. Another candidate, AR-12, has completed Phase I clinical studies for the treatment of solid tumors and hematological malignancies, and is also undergoing pre-clinical studies for various anti-microbial targets. Additionally, AR-42, an orally available therapy, is in Phase I investigator-initiated clinical studies for hematological malignancies and solid tumors. Arno Therapeutics has established license agreements with multiple institutions and a co-development agreement with Leica Biosystems Newcastle Ltd., and is headquartered in Flemington, New Jersey.

Sevion Therapeutics is a biopharmaceutical company focused on discovering, developing, and acquiring innovative therapies for cancer and immunological diseases. The company advances a pipeline of proprietary and partnered product candidates utilizing its unique antibody technology platforms. This pipeline aims to create biologic therapies targeting previously inaccessible areas, including multispanning membrane proteins and ion channels involved in various diseases. Additionally, Sevion has developed a pioneering protein nanocage system designed for the targeted delivery of nucleic acids and other therapeutic payloads to specific cells. Through its research and development efforts, Sevion is dedicated to addressing critical therapeutic needs in the treatment of cancer and inflammatory diseases.

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of oncology and hematology drug products. The company is advancing several key therapies, including ROLONTIS, a long-acting granulocyte colony-stimulating factor aimed at treating chemotherapy-induced neutropenia; Poziotinib, an irreversible tyrosine kinase inhibitor targeting specific mutations in non-small cell lung cancer; and an Anti-CD20-IFNα fusion molecule, currently in Phase I trials for relapsed or refractory non-Hodgkin’s lymphoma. Spectrum has established various partnerships, including co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd., as well as licensing agreements with notable institutions such as The University of Texas M.D. Anderson Cancer Center and ImmunGene, Inc. Founded in 1987 and headquartered in Henderson, Nevada, the company was previously known as NeoTherapeutics, Inc. before adopting its current name in December 2002.

EUSA Pharma, established in March 2015 and headquartered in the UK, is a specialty pharmaceutical company with a global presence, particularly in Europe and the USA. The company specializes in oncology and critical diseases, offering a portfolio of five approved specialty hospital products, including Caphosol®, Xenazine®, Collatamp®, Custodiol®, and Fomepizole®. EUSA Pharma focuses on addressing rare diseases and conditions like oral mucositis, a debilitating side effect of cancer treatments, with effective biopharmaceutical solutions. The firm submitted a marketing authorization application for FOTIVDA (tivozanib HCL) as a first-line therapy for renal cell carcinoma in early 2016. EUSA Pharma aims to expand its product offerings through acquisitions and in-licensing, supported by significant funding from prominent life science investors. With direct commercial operations and a distribution network that spans approximately 40 countries, EUSA Pharma is well-positioned to meet the needs of patients worldwide.